Brokerage firm Jefferies Maintains its rating on Pacira Pharmaceuticals Inc(NASDAQ:PCRX). In a research note issued to the investors, the brokerage major Lowers the price-target to $60.00 per share. The shares have been rated Buy. The rating by Jefferies was issued on Sep 26, 2016.
In a different note, Cowen & Company said it Initiates Coverage on Pacira Pharmaceuticals Inc, according to a research note issued on Sep 7, 2016. The shares have been rated ‘Market Perform’ by the firm. BMO Capital said it Initiates Coverage on Pacira Pharmaceuticals Inc, according to a research note issued on Jun 29, 2016. The shares have been rated ‘Underperform’ by the firm.
Pacira Pharmaceuticals Inc (PCRX) made into the market gainers list on Thursdays trading session with the shares advancing 1.93% or 0.71 points. Due to strong positive momentum, the stock ended at $37.52, which is also near the day’s high of $37.875. The stock began the session at $37.25 and the volume stood at 9,40,474 shares. The 52-week high of the shares is $80.25 and the 52 week low is $31.08. The company has a current market capitalization of $1,399 M and it has 3,72,78,231 shares in outstanding.
Pacira Pharmaceuticals Inc(PCRX) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $69.64M. Analysts had an estimated revenue of $68.03M. Earnings per share were $0.19. Analysts had estimated an EPS of $0.04.
Several Insider Transactions has been reported to the SEC. On Aug 17, 2016, David M Stack (CEO and Chairman) sold 15,000 shares at $45.32 per share price.Also, On Aug 17, 2016, James S Scibetta (President) sold 25,000 shares at $45.21 per share price.On Jun 8, 2016, Lauren Bullaro Riker (Vice President, Finance) sold 938 shares at $47.67 per share price, according to the Form-4 filing with the securities and exchange commission.
Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.